Skip to content
MedsAcross

Medicine

Clofarabine 20 mg/20 mL injection

Clofarabine · Intravenous
Available on requestPrescription onlyUS FDAGeneric name

Clofarabine 20 mg/20 mL injection is a generic prescription medicine for intravenous use, made by 9 labelers, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.

Availability

Available on request

Export supply from India to licensed buyers

Typical lead time

On request

Counted from payment and complete documents

Shipping

Ambient

Do not freeze. The pH range of the solution is 4.5 to 7.5 and is supplied as…

Key facts

Active ingredient (INN)
Clofarabine
Brand
Sold under the generic name
Strength
20 mg/20 mL
Dosage form
Injection
Route
Intravenous
Packs
1 vial of 20 mL and 6 more
Manufacturers
Dr. Reddy's LaboratoriesIndiaEugiaIndiaGland PharmaIndiaNovadoz PharmaceuticalsIndiaZydus LifesciencesIndiaAmneal PharmaceuticalsFosun PharmaFresenius KabiMeitheal Pharmaceuticals
Origin register
US FDA, United States
Storage
Do not freeze. The pH range of the solution is 4.5 to 7.5 and is supplied as follows: 20 mg per 20 mL (1 mg/mL) 20 mL Single-Dose Vials Packaged Individually NDC 55150-326-01 Vials containing undiluted Clofarabine Injection should be stored at 25°C (77°F), excursions permitted to 15°C to 30°C (59°F to 86°F).
Cold chain
Not required on record
Prescription status
Prescription only
Controlled substance
Not recorded as controlled
ATC code
L01BB06 Clofarabine
HS code (indicative)
3004.90Indicative only. Your customs broker confirms the final tariff code.
Marketing category
marketed
Marketed since
10 May 2017
Identifiers
RxCUI 486419DailyMed set ID 18adf4af-63ed-41e6-ab59-87085ce3e5fb, b7d3a96e-0280-4f14-b921-795996f75950, e956b1e0-2829-4872-8c09-99462d60e922 +6NDC 55150-326, 68083-386, 72266-108 +6Application ANDA212457, ANDA207831, ANDA204029 +4

Record updated 12 November 2026

Documents available

Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.

No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.

Packs

Packs from every labeler of this generic presentation.

PackCodeLabelerMarketed since
1 vial, single-dose in 1 carton / 20 mL in 1 vial, single-dose43598-309-20Dr. Reddy's LaboratoriesIndia8 November 2017
1 vial, single-dose in 1 carton / 20 mL in 1 vial, single-dose55150-326-01EugiaIndia3 October 2022
1 vial, single-dose in 1 carton / 20 mL in 1 vial, single-dose68083-386-01Gland PharmaIndia14 November 2018
1 vial, single-dose in 1 carton / 20 mL in 1 vial, single-dose72205-394-01Novadoz PharmaceuticalsIndia1 September 2026
1 vial, single-use in 1 carton / 20 mL in 1 vial, single-use49315-003-06Zydus LifesciencesIndia10 May 2017
1 vial, single-dose in 1 box / 20 mL in 1 vial, single-dose70121-1236-1Amneal Pharmaceuticals6 November 2017
1 vial, single-dose in 1 carton / 20 mL in 1 vial, single-dose72266-108-01Fosun Pharma19 August 2019
1 vial, single-use in 1 carton / 20 mL in 1 vial, single-use63323-572-70Fresenius Kabi10 May 2017
1 vial, single-dose in 1 carton / 20 mL in 1 vial, single-dose71288-128-20Meitheal Pharmaceuticals23 October 2020

Status by register

Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.

RegisterStatusSource
US FDAListed, marketedSource record for this pageChecked 12 November 2026
US FDAFirst approved 28 December 2004Drugs@FDA
EU (EMA)AuthorisedEMA medicines data
India (CDSCO)Not yet confirmed against CDSCO approval lists—
AustriaRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
BelgiumRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
BulgariaRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
CroatiaRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
CyprusRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
CzechiaRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
DenmarkRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
EstoniaRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
FinlandRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
FranceRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
GermanyRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
GreeceRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
HungaryRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
IcelandRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
IrelandRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
ItalyRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
LatviaRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
LiechtensteinRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
LithuaniaRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
LuxembourgRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
MaltaRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
NetherlandsRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
NorwayRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
PolandRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
PortugalRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
RomaniaRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
SlovakiaRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
SloveniaRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
SpainRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
SwedenRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
United StatesRegisteredUS FDA (NDC directory, openFDA)Checked 12 November 2026

Import route

Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.

Import guides are available for 25 countries. Pick one to see its route summary.

BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides

Clinical summary

Clofarabine is a nucleoside metabolic inhibitor indicated for the treatment of pediatric patients 1 to 21 years old with relapsed or refractory acute lymphoblastic leukemia after at least two prior regimens. MedsAcross supplies Clofarabine for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.

Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review

Read about Clofarabine

For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.

Data sources

Need Clofarabine 20 mg/20 mL injection for your hospital or patient?

Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.